Traditional epidemic modeling techniques, including compartmental, network, and temporal models, have historically ...

Moderna's flu vaccine candidate, mRNA-1010, shows 26.6% efficacy in a Phase 3 trial for adults 50+. Read more here.

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to ...

Moderna said on Monday its experimental influenza vaccine was found to be 26.6% more effective than a currently approved ...

Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older ...

Apr. 23, 2025 — A vaccine under development has demonstrated complete protection in mice against a deadly variant of the virus that causes bird flu. The work focuses on the H5N1 variant known as ...

May 6, 2025 — People who are given a vaccine for shingles have a 23% lower risk of cardiovascular events, including stroke, heart failure, and coronary heart disease, according to a recent study ...

The Health and Human Services Department under Kennedy took unprecedented steps to change how vaccines are evaluated, ...

Glass Lewis recommends FOR all five Askeladden Nominees, citing “detailed, coherent, and realistic strategy” and ...